IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

David White

Application No.:

Group No.:

N/A

Filed:

Herewith

Examiner:

N/A

For:

COMPOSITIONS, KITS AND METHODS FOR PROGNOSTICATION, DIAGNOSIS, PREVENTION, AND TREATMENT OF BONE-RELATED

DISORDERS AND OTHER DISORDERS

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1. This submission accompanies the new application being filed concurrently herewith

IDENTIFICATION OF PERSON MAKING STATEMENT

2. 1	I, Kerri Pollard Schray		
	(type or print name	e of person sig	gning below)
5	state the following:		
	CERTIFICATION UNDER 3	37 C.F.R. SECT	TIONS 1.8(a) and 1.10*
I here	eby certify that, on the date shown below, this correspond	ndence is being:	
E	deposited with the United States Postal Service in Commissioner for Patents, P.O. Box 1450, Alexan 37 C.F.R. SECTION 1.8(a)	-	• • • • • • • • • • • • • • • • • • • •
	with sufficient postage as first class mail.	æ	as "Express Mail Post Office to Addressee" Mailing Label No. <u>EL992152675US</u>
	TRA	NSMISSION	
	transmitted by facsimile to the Patent and Tradema	ark Office. Signat	lean Ang
Date:	September 18, 2003	_	
			lunziker
		(type a	or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 4)

Practitioner's Docket No. MPI99-130P1RCN1M

ITEMS BEING SUBMITTED

~	0 1 1 1	1	. ,
3.	Submitted	herewith	ic/are.
	Submitted	HOLOW HILL	13/ al C.

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. () An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. [] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. [X] Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:	David White				
Application No.:	09/628,495	Group No.:	1655		
Filed:	July 28, 2000	Examiner:	Diana Johannsen		
For:	COMPOSITIONS, KITS AND METHODS FOR PROGNOSTICATION,				
į	DIAGNOSIS, PREVENTION, AND TREATMENT OF BONE-RELATED				
	DISORDERS AND OTHER DISORDERS				

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"		
(other application)	(this application)		

E.	[X] A	statement	that the	content	of eac	ch "S	Sequence	Listing"	submitted	and	each	computer
	re	eadable cop	v are the	same, as i	eauire	ed in 3	37 C.F.R.	Section 1	.821(f).			

$(\]$	Because the statement is not made by a person registered to practice before the Off	fice,
-	the Statement is verified as required in 37 C.F.R. Section 1.821(b).	

Practitioner's Docket No. MPI99-130P1RCN1M

F.	. ()		omission is made in fulfilling the requirement under 3 ment that the submission includes no new matter.	7 C.F.R. Section
			statement is not made by a person registered to practice to is verified, as required in 37 C.F.R. Section 1.821(g).	pefore the Office
		AND C	CATEMENT THAT "SEQUENCE LISTING" OMPUTER READABLE COPY ARE THE SAME IF PAPERS SUBMITTED INCLUDES NO NEW MATT	ГER
4. 11	hereby	y state:		
A	. (X)		adable form submitted in this application, including those for applicant's other application, is the same as the "Sequence elate.	
В	. (X)		panying this submission, or for which a request for transfe introduce no new matter.	r from applicants
			EXTENSION OF TERM	
5. Th	e proc	ceedings herein are	for a patent application and the provisions of 37 C.F.R. Sect	tion 1.136 apply.
(a) []		ns for an extension of time under 37 C.F.R. Section 1.136 (-(4)) for the total number of months checked below:	(fees: 37 C.F.R
		tension	Fee for other than	Fee for
	<u>(ma</u>	onths)	small entity	small entity
	()	one month	\$ 110.00	\$ 55.00
		two months	\$ 390.00	\$ 195.00
		three months	\$ 890.00	\$ 445.00
	()	four months	\$1,390.00	\$ 695.00
			Fee	\$0.00
If an a	ndditio	onal extension of ti	me is required, please consider this a petition therefor.	
			for months has already been secured, and the fee pa is deducted from the total fee due for the total months or	
			Extension fee due with this reque	est \$0.00
				(Page 3 of 4

Practitioner's Docket No. MPI99-130P1RCN1M

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

5. [] Attached is a check in the sum	of\$
[] Charge Account No. <u>501668</u> A duplicate of this transmittal	
	FEE DEFICIENCY
8. (X) If any additional extension and	/or fee is required, charge Account No. 501668
September 18, 2003	MILLENNIUM PHARMACEUTICALS, INC.
	L. Dinsen
	By test value of
	Kerri Pollard Schray
	Attorney/Agent for Applicant
	Registration No. 47,066
	75 Sidney Street

Cambridge, MA 02139 Telephone – (617) 551-3676 Facsimile – (617) 551-8820